文献速递免疫规划

不同厂家Sabin株脊髓灰质炎灭活疫苗序贯接种在婴儿中的免疫原性与安全性:随机、盲法、对照试验

Immunogenicity and safety of sequential Sabin strain inactivated poliovirus vaccine from different manufacturers in infants: Randomized, blinded, controlled trial.
PubMed 文献 · Vaccine · 2025-07-03

本研究在中国湖北省孝感市于2024年5月20日至2024年9月6日纳入200名≤12月龄健康婴儿,随机分为不同厂家Sabin株脊髓灰质炎灭活疫苗(sIPV)第三剂试验组与同厂家对照组,评估序贯接种的免疫原性与安全性。结果显示试验组1、2、3型脊灰病毒血清阳转率分别为79.52%、67.47%、74.70%,对照组为73.56%、49.43%、63.22%,仅2型差异有统计学意义(P=0.017);两组不良事件发生率无显著差异,未报告与疫苗相关的严重不良事件。

要点

  • 不同厂家sIPV第三剂序贯接种的2型血清阳转率高于同厂家对照组(67.47% vs 49.43%,P=0.017)。
  • 1型与3型血清阳转率两组差异未达统计学显著(P=0.360、P=0.106)。
  • 最常见全身不良事件为发热,两组不良事件发生率无显著差异,未报告疫苗相关严重不良事件。

核心结论

  • 不同厂家sIPV序贯接种与初始疫苗相比显示出更优的免疫原性,安全性无显著差异,提示使用不同厂家疫苗进行序贯接种是可行且有效的选择。

研究设计与样本

  • 随机、盲法、对照试验,纳入200名≤12月龄健康婴儿,随机分为不同厂家sIPV第三剂试验组与同厂家对照组,研究地点为中国湖北省孝感市,时间为2024年5月20日至2024年9月6日,免疫原性采用符合方案集分析、安全性采用安全性人群分析。

主要发现

  • 试验组1、2、3型脊灰病毒血清阳转率分别为79.52%、67.47%、74.70%,对照组分别为73.56%、49.43%、63.22%,P值分别为0.360、0.017、0.106。
  • 最常见全身不良事件为发热,两组不良事件发生率无显著差异,未报告与疫苗相关的严重不良事件。

临床怎么用

  • 作者认为,使用不同厂家疫苗进行序贯接种是可行且有效的选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The National Immunization Program allows using a different manufacturer's vaccine for follow-up doses when the same vaccine is unavailable. This study aimed to evaluate the safety and immunogenicity of administering a third dose of Sabin strain (sIPV) from a different manufacturer in infants who had previously received two doses of sIPV. METHODS: This randomized, blinded, controlled trial enrolled 200 healthy infants (≤12 months) to assess the safety and immunogenicity of sequential vaccination, who were randomly assigned to receive a third dose of sIPV from either a different manufacturer (experimental group) or the same manufacturer as the first two doses (control group). The study took place in Xiaogan City, Hubei Province, China, from 20 May 2024 to 6 September 2024. Immunogenicity and safety were assessed using per-protocol and safety populations, respectively. RESULTS: The seroconversion rates for poliovirus types 1, 2, and 3 were 79.52 %, 67.47 %, and 74.70 % in the experimental group, respectively, compared to 73.56 %, 49.43 %, and 63.22 % in the control group, with P-values of 0.360, 0.017, and 0.106, respectively. The most common systemic adverse event (AE) was fever, and no significant differences in the incidence of AEs between the two groups were observed. No serious adverse events related to vaccines were reported. CONCLUSION: Sequential vaccination with sIPV from different manufacturers demonstrated superior immunogenicity compared to the initial vaccine, with no significant safety differences, indicating that using vaccines from different manufacturers for sequential dosing is a feasible and effective option.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wang L, Han W, Li D, et al. Immunogenicity and safety of sequential Sabin strain inactivated poliovirus vaccine from different manufacturers in infants: Randomized, blinded, controlled trial. Vaccine. 2025. PMID: 40614614. doi:10.1016/j.vaccine.2025.127448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。